Camilla Sandberg
Vorstandsvorsitzender bei MIRIS HOLDING AB
Aktive Positionen von Camilla Sandberg
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MIRIS HOLDING AB | Vorstandsvorsitzender | 04.10.2016 | - |
NEXTCELL PHARMA AB | Direktor/Vorstandsmitglied | 01.01.2017 | - |
Independent Dir/Board Member | 01.01.2017 | - | |
MONIVENT AB | Direktor/Vorstandsmitglied | - | - |
Independent Dir/Board Member | - | - |
Karriereverlauf von Camilla Sandberg
Ehemalige bekannte Positionen von Camilla Sandberg
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BioLamina AB
BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Vertrieb & Marketing | - | - |
Ausbildung von Camilla Sandberg
University of Oslo | Masters Business Admin |
Statistik
International
Schweden | 5 |
Norwegen | 2 |
Operativ
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Chief Executive Officer | 1 |
Sektoral
Health Technology | 4 |
Electronic Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
MIRIS HOLDING AB | Electronic Technology |
NEXTCELL PHARMA AB | Health Technology |
MONIVENT AB | Health Technology |
Private Unternehmen | 1 |
---|---|
BioLamina AB
BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Health Technology |
- Börse
- Insiders
- Camilla Sandberg
- Erfahrung